Sakar Healthcare Limited
NSE: SAKARMarket Closed • NSE
Day range
52 week range
Sakar Healthcare Limited closed at INR1011.50 (+0.91%) on volume 2.09x its 20-day average, trading 17.75% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -9.1% QoQ
2024-09-13
AGM Announced
Annual General Meeting
2023-09-14
AGM Announced
Annual General Meeting
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.22x
High Cash Flow Conversion: CFO/PAT averaged 1.62x over last 3 years
Risks
Stretched Valuation: Trading at a high P/E multiple of 73.6x
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| — | Annual General Meeting | Annual General Meeting | — | 13 Sept 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 14 Sept 2023 |
| — | Annual General Meeting | Annual General Meeting | — | 12 Sept 2022 |
| — | Annual General Meeting | Annual General Meeting | — | 16 Sept 2021 |
| — | Annual General Meeting | Annual General Meeting | — | 16 Sept 2020 |
| — | Annual General Meeting | Annual General Meeting | — | 06 Sept 2019 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.92 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.48L | 84.75 | 0.32% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.77L | 74.39 | 0.82% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.17L | 183.15 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.15L | 55.26 | 0.26% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.11L | 24.91 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.10L | 100.67 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.05L | 31.20 | 0.99% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products[1]
IndiaHealthcare
Is Sakar Healthcare Limited Shariah compliant?
Sakar Healthcare Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (3.2%) complies with AAOIFI threshold (≤ 33%).
What is Sakar Healthcare Limited's current valuation relative to peers?
Sakar Healthcare Limited trades at a P/E of 73.6x compared to the sector median of 37.6x, and a Price-to-Book of 6.9x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.22x and a Net Debt to EBITDA ratio of 1.03x. Interest coverage is 8.6x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 10.4% while net profit growth averaged 20.1%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-09. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.